Fig. 1
Flow chart of study design. HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICIs, immune checkpoint inhibitors; TACE, transarterial chemoembolization; TKIs, tyrosine kinase inhibitors.
Fig. 1 | Scientific Reports
